Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: January 29, 2009
Last updated: April 7, 2011
Last verified: April 2011
This is a Phase I, open-label, single sequence, crossover study to be conducted in healthy adult subjects. There will be a screening visit, three treatment periods, and a follow-up visit. In Period 1, subjects will receive a single dose of eltrombopag on Day 1, and PK sampling will occur for 72 hours. In Period 2, subjects will receive LPV/RTV for 14 days with PK sampling for 12 hours. In Period 3, subjects will receive a single dose of eltrombopag with LPV/RTV on Day 1 only with PK sampling for 72 hours. Subjects will return for a follow-up visit within 10 to 14 days of the last dose of study drugs.

Condition Intervention Phase
Hepatitis C
Drug: Eltrombopag
Drug: Lopinavir/Ritonavir
Drug: Eltrombopag and Lopinavir/Ritonavir
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and When Co-administered in Healthy Adult Subjects.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Pharmacokinetic parameters per the protocol [ Time Frame: sixteen days ]

Secondary Outcome Measures:
  • Safety parameters including vital signs, laboratory assessments, ECG measurements and adverse events reporting [ Time Frame: sixteen days of treatment and follow-up period. ]
  • Pharmacokinetic parameters per the protocol [ Time Frame: sixteen days ]

Enrollment: 40
Study Start Date: January 2009
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Period 2
Treatment B
Drug: Lopinavir/Ritonavir
Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
Active Comparator: Period 1
Treatment A
Drug: Eltrombopag
Eltrombopag 100 mg single oral dose
Active Comparator: Period 3
Treatment C
Drug: Eltrombopag and Lopinavir/Ritonavir
Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects with no clinically significant abnormality identified by physician by evaluation of medical history, physical examination, clinical laboratory tests or electrocardiogram (ECG).
  • Able to swallow and retain oral medication.
  • Male and female subjects between the ages of 18 to 64 years of age inclusive, at the time of signing the informed consent.
  • Subject is able to understand and comply with the protocol requirements, instructions and restrictions.
  • Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the consent form. Signed informed consent must be on file prior to screening procedures.
  • Body weight ≥ 50kg (110 lbs) for men and ≥ 45 kg (99 lbs) for women and body mass index (BMI) of 18.5 to 29.9 kg/m2 inclusive.
  • Male subjects, who are not surgically sterile, must agree on abstinence or to use a double barrier method, such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository). This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of medication.-
  • A female subject is eligible to participate if she is neither pregnant nor lactating, and falls into one of the following categories:

    • non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophorectomy, or postmenopausal females defined as being amenorrheic for greater than 1 year and having serum estradiol and follicle stimulating hormone levels consistent with menopause.
    • child-bearing potential with negative β human chorionic gonadotropin (βhCG) test and agrees to comply with recognized non-hormonal contraceptive methods from screening or at least two weeks prior to first dose (whichever is earlier) until the follow-up visit. Recognized non-hormonal contraceptive methods include: complete abstinence from intercourse, two forms of barrier contraception (e.g. condom with spermicide, or diaphragm with spermicide), or intrauterine device (IUD).

Exclusion Criteria:

  • History of Gilbert's syndrome.
  • Any previous history of deep vein thrombosis or any other thromboembolic event. 3. History of thrombocytopenia or bleeding due to abnormal platelet number or function. 4. Clotting factor abnormalities associated with hypercoagulability, specifically Factor V Leiden, Protein C or Protein S deficiency or antithrombin III deficiency. 5. Elevated blood pressure (BP) at screening (systolic >140 mm Hg, diastolic >85 mm Hg). If the subject's BP is elevated on the first measurement, complete two additional BP measurements 2 minutes apart and average the three assessments to evaluate this criteria. If averaged BP exceeds the safety criteria, the subject should be excluded.

    6. History of atrial fibrillation, mitral valve prolapse, significant heart murmur or vascular bruit. 7. Prolonged QTc interval (Bazett's) at screening (for females > 450 msec and for males > 430 msec). If the QTc interval is prolonged on the initial ECG, then complete two additional ECGs 5 minutes apart and take the average QTc measurements of all three ECGs to evaluate this criteria. If averaged QTc exceeds the safety criteria, the subject should be excluded. 8. Female subjects currently receiving hormone replacement therapy (HRT). 9. Positive for HIV, hepatitis B virus or hepatitis C virus assays at screening.

    10. Positive urine drug screen including alcohol at screening or pre-dose (Day -1).

    11. History of alcohol/drug abuse or dependence within 12 months of the study. RM2008/00650/00 CONFIDENTIAL TPL111716 25 CONFIDENTIAL RM2008/00650/00 TPL111716 26 12. History of alcohol consumption in the past six months exceeding 7 units/week for women and 14 units/week for men (where 1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor). 13. Urinary cotinine levels indicative of smoking at screening or pre-dose (Day -1).

History of regular use of tobacco- or nicotine-containing products within 6 months prior to screening. 14. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication. 15. Exposure to more than four new chemical entities within 12 months prior to the first dosing day. 16. Use of prescription or non-prescription drugs (including aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]), vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer, such as St. John's Wort) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety. 17. Subjects who have donated plasma within 7 days prior to the screening visit or where participation in this study would result in donation of blood in excess of 500 mL within a 56-day period. 18. History of sensitivity to any of the study medications, or components thereof.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00833378

United States, New York
GSK Investigational Site
Buffalo, New York, United States, 14202
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00833378     History of Changes
Other Study ID Numbers: 111716
Study First Received: January 29, 2009
Last Updated: April 7, 2011

Keywords provided by GlaxoSmithKline:
Drug interaction, SB-497115 (eltrombopag), Kaletra (Lopinavir, Ritonavir),thrombocytopenia, pharmacokinetics

Additional relevant MeSH terms:
Hepatitis C
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Liver Diseases
Digestive System Diseases
Blood Platelet Disorders
Hematologic Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on April 24, 2017